GPC3 and hepatocellular carcinoma: However, referencing a few available reports from phase I clinical trials using anti‐GPC3 CAR‐T cells, CAR‐T cell therapy for HCC patients has not demonstrated much effectiveness in terms of response rates among subjects [41].